Dr. Kun Ping Lu received his MD from Fujian Medical University, PhD from Duke University, and postdoctoral training at Salk Institute. He had been a faculty at Harvard Medical School for 25 years, becoming the Founding Division Chief and Program Director of Translational Therapeutics at Beth Israel Deaconess Medical Center, and Associate Member at Broad Institute, before joining Western University in 2022 to provide leadership in discovering and developing novel biotherapeutics and biodiagnostics. In long-term collaboration with Dr. Xiao Zhen Zhou, Dr. Lu has discovered Pin1-catalyzed cis-trans proline isomerization as a unique signaling mechanism, whose dysregulation can have the opposite effect on cancer and Alzheimer’s disease, but can be effectively targeted by Pin1 inhibitors and/or stereo-specific antibodies. He has published ~200 papers including 14 papers in Cell, Nature and Science, and earned many awards, including elections to the Association of American Physicians, and to the AAAS Fellow of the American Association for the Advancement of Science.